Raymond James Trust N.A. Acquires 386 Shares of Zoetis Inc. (NYSE:ZTS)

Raymond James Trust N.A. boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,786 shares of the company’s stock after purchasing an additional 386 shares during the quarter. Raymond James Trust N.A.’s holdings in Zoetis were worth $2,737,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Webster Bank N. A. grew its stake in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the last quarter. Private Wealth Management Group LLC bought a new position in Zoetis in the fourth quarter worth $33,000. Gladius Capital Management LP acquired a new stake in Zoetis during the fourth quarter worth $40,000. Neo Ivy Capital Management bought a new stake in Zoetis in the 4th quarter valued at $40,000. Finally, LRI Investments LLC acquired a new position in shares of Zoetis in the 1st quarter valued at $43,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ZTS shares. The Goldman Sachs Group lowered their target price on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus boosted their price target on Zoetis from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Finally, HSBC dropped their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $217.11.

Zoetis Price Performance

Shares of Zoetis stock traded up $1.32 during trading on Monday, reaching $182.22. The company’s stock had a trading volume of 82,126 shares, compared to its average volume of 2,698,170. The stock has a 50-day moving average price of $178.56 and a two-hundred day moving average price of $174.78. The stock has a market capitalization of $83.15 billion, a P/E ratio of 34.86, a price-to-earnings-growth ratio of 2.79 and a beta of 0.86. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the firm posted $1.41 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.